Notice of Special Interest: Administrative Supplements for Cancer Moonshot awardees and Cancer Center Support Grants (CCSG) to Support
Development of an "Immune Radiation Response Index (i-RRI)" for Immune Cells from Normal and Tumor Microenvironments.
Recent evidence indicates that ionizing radiation can enhance immune responses to tumors. Advances in radiation delivery techniques allow hypo-fractionated delivery of conformal radiotherapy. Hypofractionation or other modifications of standard fractionation may improve radiation's ability to promote immune responses to tumors. Other novel delivery options may also affect immune responses, including T-cell activation and tumor-antigen presentation changes. However, there is limited understanding of the immunologic impact of hypo- and unique multi-fractionated radiotherapy regimens, as these observations are relatively recent. Divergence of approaches and findings between preclinical studies and clinical trials highlights the need for evaluating the design of future clinical studies with particular emphasis on radiation dose and fractionation, immune biomarkers, and selecting appropriate endpoints for combination radiation/immune modulator trials, recognizing that direct effect on the tumor and potential abscopal effect may well be different. Similarly, preclinical studies should be designed as much as possible to model the intended clinical setting.
Please direct all inquiries to:
Mansoor M Ahmed, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5700
Email: ahmedmm@mail.nih.gov
Novel collaborations to support adoption, adaptation, and integration of ITCR tools and resources.
These FOAs support currently funded NCI R01, U01 and U24 projects proposing to expand or accelerate progress of the parent study by incorporating informatics methods, tools or resources developed through the ITCR program.
Budget: Up to $100,000 Direct Costs per year over a two-year period.
